Mainland France has seen an explosion of chikungunya outbreaks this summer and local officials are hunting down the tiger mosquitoes responsible for spreading the virus. Meanwhile, the United States ...

The suspension of the license is effective immediately and requires Valneva to stop shipping and selling of Ixchiq in the United States. The suspension follows the US FDA’s decision on August 6, 20251 ...

The United States Food and Drug Administration (FDA) has suspended the licence of one of the two chikungunya vaccines ...

Mainland France has recorded an unprecedented rise in chikungunya cases this summer as the tiger mosquito spreads across the ...

Worrisome new signals caused the U.S. FDA – which earlier this month OK’d revised labeling for Valneva SE’s chikungunya virus ...

The U.S. Food and Drug Administration is suspending the biologics license for the live-attenuated chikungunya vaccine, Ixchiq ...

According to the vaccine's maker, Valneva, the FDA based its decision to suspend the shot on four new serious adverse events ...

The agency said it had become aware of more reports of serious adverse events, leading center director Vinay Prasad to ...

There have been 4 new reports of serious adverse events related to Ixchiq based on updated Vaccine Adverse Event Reporting System data.

European shares closed lower on Monday, giving back Friday's gains on optimism around U.S. monetary policy easing, while JDE ...

Less than three weeks after lifting a pause on the use of Valneva’s chikungunya vaccine Ixchiq, the FDA has done an ...

Shares of French drugmaker Valneva slumped more than 20% on Monday after the U.S. Food and Drug Administration suspended the ...